Does Obesity Cause Type 2 Diabetes? OR Is it the Opposite? A Commentary

Pediatric Diabetes,Volume 0, Issue ja, -Not available-.
Source: Pediatric Diabetes - Category: Endocrinology Authors: Source Type: research

Related Links:

This study showed that potential vicious cycles underlying ARDs are quite diverse and unique, triggered by diverse and unique factors that do not usually progress with age, thus casting doubts on the possibility of discovering the single molecular cause of aging and developing the single anti-aging pill. Rather, each disease appears to require an individual approach. However, it still cannot be excluded that some or all of these cycles are triggered by fundamental processes of aging, such as chronic inflammation or accumulation of senescent cells. Nevertheless, experimental data showing clear cause and effect relationships...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
Authors: Wu HX, Tang J, Li L, Liu SP, Zhou ZG, Yang JX, Yan DW, Zhou HD Abstract Type 2 diabetic patients are becoming younger and having a tendency to family aggregation, they are easily suspected as maturity-onset diabetes of young (MODY) in the outpatient clinic and send to genetic testing. 9 diabetic families were compared in our outpatient clinic who met the primary diagnosis criteria of MODY. Detailed clinical features and laboratory data including gene sequence were collected and analyzed. The patients met the primary clinical diagnostic criteria of MODY for genetic testing at the first look. However, member...
Source: Endocrine Journal - Category: Endocrinology Tags: Endocr J Source Type: research
ConclusionSynchronous VHR and BS in a bariatric unit is feasible with low recurrence rate. Laparoscopic VHR has lower complication rates than open, apart from seroma formation. Patients with diabetes have higher risk of infection.
Source: Surgical Endoscopy - Category: Surgery Source Type: research
Authors: Pouwels S, Topal B, Knook MT, Celik A, Sundbom M, Ribeiro R, Parmar C, Ugale S Abstract INTRODUCTION: Obesity, defined as a Body Mass Index (BMI) of ≥30 kg/m2, is the most common chronic metabolic disease worldwide and its prevalence has been strongly increasing. Obesity is associated with various diseases such as cardiovascular disease, type 2 diabetes and hypertension. Regarding heart rhythm disorders, obesity is associated with an increase in atrial fibrillation (AF), the most common arrhythmia in clinical practice. AF is associated with an increased cardiovascular morbidity and mortality. Obesity, a...
Source: Expert Review of Cardiovascular Therapy - Category: Cardiology Tags: Expert Rev Cardiovasc Ther Source Type: research
Authors: Kumar S Abstract The prevalence of obesity-associated diabetes is increasing dramatically in the UK and worldwide. Obesity, particularly abdominal obesity, is not only associated with other cardiovascular risk factors, but is an independent cardiometabolic risk factor for diabetes and cardiovascular disease. Thus, the focus of obesity management, especially in patients with prediabetes and Type 2 diabetes, should encompass cardiometabolic risk reduction as well as weight loss. Lifestyle and diet modification should form the basis of all effective strategies for weight reduction. Pharmacotherapy provides an...
Source: Expert Review of Endocrinology and Metabolism - Category: Endocrinology Tags: Expert Rev Endocrinol Metab Source Type: research
Authors: Landau D, Segev Y Abstract Insulin resistance, the key mechanism in Type 2 diabetes mellitus (T2DM) is also associated with the deregulation of other glucose homeostasis pathways, such as the growth hormone (GH)-IGF-I system. In this review, we summarize the endocrine and renal GH-IGF axis changes in db/db mice, a model of T2DM, and compare it with the nonobese diabetic mouse model of T1DM. In the latter, elevated circulating GH levels (associated with kidney disease) could be ameliorated with the use of GH antagonists. Contrary to that, in the obese db/db mice, serum GH and IGF-I levels are decreased and ...
Source: Expert Review of Endocrinology and Metabolism - Category: Endocrinology Tags: Expert Rev Endocrinol Metab Source Type: research
Authors: Hoo RL, Yeung DC, Lam KS, Xu A Abstract Obesity is an important risk factor for a cluster of metabolic and cardiovascular diseases, including insulin resistance, Type 2 diabetes, nonalcoholic fatty liver disease and atherosclerosis. Systemic low-grade inflammation, characterized by elevated circulating concentrations of proinflammatory factors, has recently been proposed to be a key mediator that links obesity with its medical complications. Adipose tissue is now recognized as the major contributor to systemic inflammation associated with obesity. As obesity develops, adipose tissue is infiltrated with act...
Source: Expert Review of Endocrinology and Metabolism - Category: Endocrinology Tags: Expert Rev Endocrinol Metab Source Type: research
Authors: Meigs JB Abstract The phenomenon of risk factor clustering is known as metabolic syndrome. Metabolic syndrome is an aggregation of metabolic risk factors for cardiovascular disease and Type 2 diabetes. Risk factor clustering occurs in individuals, but its specific cause(s) remain incompletely known. Insulin resistance and central obesity are involved in many cases. There are five current definitions of metabolic syndrome, but they do not identify equivalent phenotypes, and the most widely promoted definition, Adult Treatment Panel 3 metabolic syndrome, is not uniformly associated with insulin resistance. M...
Source: Expert Review of Endocrinology and Metabolism - Category: Endocrinology Tags: Expert Rev Endocrinol Metab Source Type: research
Authors: Albrechtsen NJW, Kuhre RE, Deacon CF, Holst JJ Abstract Degradation-resistant glucagon-like peptide-1 (GLP-1) mimetics and GLP-1 enhancers (inhibitors of dipeptidyl peptidase-4, the enzyme which degrades and inactivates GLP-1) have been used for treatment of type 2 diabetes mellitus since 2005-2006. Cutting-edge research is now focusing on uncovering the secretory mechanisms of the GLP-1-producing cells (L-cells) with the purpose of developing agonists that enhance endogenous hormone secretion. Since GLP-1 co-localizes with other anorectic peptides, cholecystokinin, oxyntomodulin/glicentin and peptide YY, ...
Source: Expert Review of Endocrinology and Metabolism - Category: Endocrinology Tags: Expert Rev Endocrinol Metab Source Type: research
ConclusionOur study demonstrated that if standardized indicators are investigated in population-based samples, the effectiveness of T2DM care can be monitored by ad hoc surveys. The systematic application of this approach completed with the detailed documentation of the applied therapies could demonstrate the public health impact of certain modifications in T2DM care. An overall improvement in metabolic control (glycaemic control, lipid status and obesity) was observed, which was not accompanied by improved therapeutic target achievement for systolic blood pressure.
Source: Diabetes Therapy - Category: Endocrinology Source Type: research
More News: Diabetes | Diabetes Type 2 | Eating Disorders & Weight Management | Endocrinology | Obesity | Pediatrics